The article didn't help, but most likely it was something that was planned to happen in case Musclepharm didn't seek financing before the Q1 earnings announcement.
I would have done the exact same thing....to reduce risk and to discipline Brad and Musclepharm's board.
I think it is very clear that the SEC has not been able to turn Musclepharm into some exemplary company.